SARS-CoV
Gene silencing can be achieved by introducing into cells a short "antisense oligonucleotide" that is complementary to an RNA target. This experiment was first done by Zamecnik and Stephenson in 1978 and continues to be a useful approach, both for laboratory experiments and potentially for clinical applications (antisense therapy). Several viruses, such as influenza viruses Respiratory syncytial virus (RSV) and SARS coronavirus (SARS-CoV), have been targeted using antisense oligonucleotides to inhibit their replication in host cells.